We are live on ! Find out more

Precigen

PGEN

Market cap $2.45B

6.85 USD

+0.17

2.54%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

6.82

-0.03

0.44%

1 day

2.54%

5 days

-3.79%

1 month

-0.15%

3 months

51.21%

6 months

100.29%

Year to date

60.05%

1 year

65.46%

5 years

16.3%

10 years

-74%

About: Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Employees: 47

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 52.9%

Neutral 41.2%

Negative 5.9%

Zacks Investment Research

Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?

Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.

Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?

Zacks Investment Research

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Zacks Investment Research

5 Biotech Stocks Worth Adding to Your Portfolio Now

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.

5 Biotech Stocks Worth Adding to Your Portfolio Now

Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers

Biotech in the News: The Longview The Company's New Drug, the First FDA-Approved Therapy for Recurrent Respiratory Papillomatosis (RRP), is Delivering Strong Commercial Traction While Highlighting the Broader Potential of Its Proprietary AdenoVerse Therapeutic Platform in HPV-Associated Cancers GERMANTOWN, MD / ACCESS Newswire / August 25, 2026 / For Germantown, MD-based Precigen Inc. (NASDAQ:PGEN), the second quarter marked a commercial inflection. PAPZIMEOS (zopapogene imadenovec-drba) generated $53.1 million in net product revenue-more than double the prior quarter-and helped the company achieve quarterly profitability.

Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers

Zacks Investment Research

Reasons Why Investors Should Consider Betting on PGEN Stock

Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.

Reasons Why Investors Should Consider Betting on PGEN Stock

Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why Precigen, Inc. (PGEN) is a Great Choice

Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Precigen, Inc. (PGEN) is a Great Choice

Precigen: Has To Grow Into Its Valuation

Precigen surged 266% on PAPZIMEOS FDA approval but now trades at a premium valuation near $2.24 billion. PAPZIMEOS, the sole revenue driver, reached $53.1 million in Q2 with COGS being just around $2.8 million. PGEN's pipeline faces stiff competition, with most candidates showing weaker efficacy than approved or late-stage rivals.

Precigen: Has To Grow Into Its Valuation

Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement

Precigen, Inc. is upgraded to a Strong Buy, driven by surging PAPZIMEOS revenues and FDA approval for recurrent respiratory papillomatosis (RRP). PGEN achieved profitability in Q2 2026 with PAPZIMEOS revenues doubling quarter-over-quarter to $53.1 million and secured seven years of U.S. market exclusivity. Potential European approval of PAPZIMEOS and expansion of the AdenoVerse Immunotherapy platform, notably PRGN-2009, could unlock significant new market opportunities.

Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement

Precigen, Inc. (PGEN) Q2 2026 Earnings Call Transcript

Precigen, Inc. (PGEN) Q2 2026 Earnings Call Transcript

Precigen, Inc. (PGEN) Q2 2026 Earnings Call Transcript

Precigen Q2 Earnings Call Highlights

Precigen NASDAQ: PGEN reported a sharp increase in second-quarter revenue from its PAPZIMEOS launch, with the company reaching quarterly profitability less than a year after the therapy's August 2025 FDA approval for adults with recurrent respiratory papillomatosis, or RRP.

Precigen Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™